Navigation Links
InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
Date:2/3/2009

s safe and generally well tolerated. In CAPACITY 2, 83% and 90% of surviving, lung transplant-free patients completed therapy per protocol in the pirfenidone and placebo groups, respectively, and 82% and 90%, respectively, in CAPACITY 1. The percentage of patients discontinuing treatment due to an adverse event was 12% and 8% in the pirfenidone and placebo groups, respectively, in CAPACITY 2, and 14% and 8%, respectively, in CAPACITY 1.

There was no difference between pirfenidone and placebo in the percentage of patients that experienced a serious adverse event (SAE). An SAE was reported in 35% and 33% of pirfenidone and placebo groups, respectively, in CAPACITY 2 and in 31% and 30%, respectively, in CAPACITY 1. In both studies, the incidence of Grade 3 or Grade 4 laboratory abnormalities was similar between patients treated with pirfenidone or placebo.

The pattern of adverse events was in general comparable to that observed in previous clinical studies of pirfenidone. The most common adverse events occurring more than 1.5 times in the pirfenidone 2403 mg group as compared to placebo in either study were nausea (35% vs. 18% in CAPACITY 2 and 38% vs. 16% in CAPACITY 1), rash (31% vs. 10% and 34% vs. 13%), fatigue (28% vs. 21% and 33% vs. 20%), diarrhea (25% vs. 17% and 33% vs. 21%), dyspepsia (17% vs. 9% and 21% vs. 6%), and dizziness (19% vs. 10% and 18% vs. 10%). Rash was generally mild to moderate in both studies; only 2 patients (1 in each CAPACITY study) receiving pirfenidone 2403 mg experienced a severe rash, and only 4 patients in each study discontinued study treatment due to a rash or photosensitivity. There was no difference in the incidence of skin cancer between patients treated with pirfenidone or placebo.

Low-dose Treatment Group

A low-dose group at 1197 mg per day was included in CAPACITY 2 to explore dose-response relationships in a descriptive fashion. In general, on efficacy o
'/>"/>

SOURCE InterMune
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. InterMune to Present at J.P. Morgan Healthcare Conference
2. InterMune to Present at Deutsche Bank Biotech Boston Confab
3. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
4. InterMune to Release Third Quarter 2008 Financial Results on November 6
5. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
6. InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
7. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
8. InterMune to Present at Canaccord Adams Conference
9. InterMune Reports Second Quarter 2008 Financial Results and Business Highlights
10. InterMune to Present at BMO Healthcare Conference
11. InterMune to Release Second Quarter 2008 Financial Results and Provide Business Update on July 31
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 /CNW/ - Sunovion Pharmaceuticals ... APTIOM TM (eslicarbazepine acetate) for use as a ... in patients with epilepsy who are not satisfactorily controlled ... for use in patients under 18 years of age. ... common neurological disorders and according to Epilepsy Canada, it ...
(Date:7/11/2014)... Cayenne Medical, Inc., a privately ... soft tissue reconstruction segment, announced the worldwide launch ... involving the shoulder and extremities. The SureLock System ... deployment method. The unique delivery eliminates manual tensioning ... or anchor displacement (also commonly know as anchor ...
(Date:7/10/2014)... 10, 2014 Product and process ... low abundance and are often “lost in the ... , Join presenters Dr. Rowel Tobias, Senior Scientist, ... Anders, Head of Quality at Nanotherapeutics, Inc., to ... can speed detection and quantitation while achieving the ...
(Date:7/10/2014)... 10, 2014 Understanding the need for ... lines, and the gap that currently exists in this ... its industry-leading portfolio of validated ion channel and GPCR ... cell lines, as ion channels control many critical physiological ... activity creates the potential to treat a variety of ...
Breaking Biology Technology:Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 3Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3
... Emmanuel Labourier , Ambion, Inc , ... from the same sample Enrich for , ... , for assessing siRNA or miRNA expression and ... (siRNAs) and , microRNAs (miRNAs) have emerged as ...
... , High ... Only ethically sourced tissue is used , Custom RNA isolations from tissue ... Begins at the Source , Use ... that you are getting the highest , quality ...
... In Vitro Translation Kit , ... of protein than reticulocyte , lysate systems , ... biological activity than other E. coli , lysate systems ... researchers studying protein function and , ...
Cached Biology Technology:Isolate It All: siRNA miRNA , Total RNA Native Protein 2Isolate It All: siRNA miRNA , Total RNA Native Protein 3Isolate It All: siRNA miRNA , Total RNA Native Protein 4Isolate It All: siRNA miRNA , Total RNA Native Protein 5Isolate It All: siRNA miRNA , Total RNA Native Protein 6Isolate It All: siRNA miRNA , Total RNA Native Protein 7Isolate It All: siRNA miRNA , Total RNA Native Protein 8Isolate It All: siRNA miRNA , Total RNA Native Protein 9High Quality RNA Isolation Services 2Increase Protein Activity and Yield 2Increase Protein Activity and Yield 3
(Date:7/11/2014)... The Chinese University of Hong Kong, BGI and other ... to salt tolerance, with implication for improving this important ... online in Nature Communications provides an effective ... , Soybean is an important crop for the world. ... less genetic diversities than their wild counterparts. Among the ...
(Date:7/11/2014)... WASH. July 11, 2014 Researchers have ... three-dimensional images. The new technology, called Virtual Finger, ... small structures like neurons and synapses using the ... unique technology makes 3D imaging studies orders of ... at an unprecedented level across many areas of ...
(Date:7/11/2014)... cannabinoid receptor type 1 can inhibit voltage-gated ... reduce neurotransmitter release. However, some scholars demonstrated ... extracellular Ca2+ influx and increase neurotransmitter release. ... Hospital Affiliated to Tongji Medical College, Huazhong ... whole cell voltage-clamp and calcium imaging in ...
Breaking Biology News(10 mins):BGI reports a novel gene for salt tolerance found in wild soybean 2Virtual finger enables scientists to navigate and analyze complex 3D images 2
... to read a mouse,s mind, it takes some fluorescent protein ... Stanford scientists have demonstrated a technique for observing hundreds of ... real time, and have linked that activity to long-term information ... studying new therapies for neurodegenerative diseases such as Alzheimer,s. ...
... about to take up residence in the laboratories of Virginia ... to learn more about the water-running lizard,s ability to dart ... it increases its locomotion efficiency by producing more force on ... And these engineers are surprised at how some frog ...
... study led by an international team of biologists has identified some ... of their brain at a time. The study was published ... headed by scientists at UCLA and the University of Toronto. It ... half awake and asleep. Findings from this study may explain the ...
Cached Biology News:Stanford researchers develop tool for reading the minds of mice 2Nature's phenomena might teach Virginia Tech engineers new tricks 2Nature's phenomena might teach Virginia Tech engineers new tricks 3New study shows how seals sleep with only half their brain at a time 2
... 20 System revolutionizes DNA sequencing, delivering sequence ... The Genome Sequencer 20 System includes: ... consumables for library construction, amplification, and sequencing ... novo assembly The instrument ...
... Proteolytic degradation is critical to the ... and regulatory proteins as important and ... metabolism, heat shock and stress response, ... receptors and ion channels, cell cycle ...
Compound(s) tested through a broad panel of 38 ligand binding and enzyme assays targeting the Central Nervous System. Used to determine selectivity and potential CV/Renal liabilities of compounds....
... demonstrated that oxidative stress is involved in ... stress is the condition in which an ... exist leading to the damage of a ... stress is through several antioxidant systems4 that ...
Biology Products: